Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: Implications for therapy

Leukemia

Volumn 26, Issue 6, 2012, Pages 1356-1364

  Gupta, M ^a   Han, J J ^a   Stenson, M ^a   Wellik, L ^a   Witzig, T E ^a  

^a MAYO CLINIC   (United States)

Author keywords

HDAC3; LBH589; Lymphoma; Mcl 1; STAT3

Indexed keywords

HISTONE DEACETYLASE 3; JANUS KINASE 2; PANOBINOSTAT; PROTEIN P300; STAT3 PROTEIN;

ACETYLATION; ARTICLE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACETYLATION; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 84862019471     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.340     Document Type: Article

References (40)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
2. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996. (Pubitemid 37087056)
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
4. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207.
5. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662. (Pubitemid 34987786)
6. Darnell Jr JE. STATs and gene regulation. Science 1997; 277: 1630-1635. (Pubitemid 27446219)
7. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-5318. (Pubitemid 47255917)
8. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515-1523. (Pubitemid 351213441)
9. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-3713.
10. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307: 269-273. (Pubitemid 40116244)
11. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370 (Part 3): 737-749. (Pubitemid 36399066)
12. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002; 9: 3-16. (Pubitemid 34155860)
13. Bannister AJ, Miska EA, Gorlich D, Kouzarides T. Acetylation of importin-alpha nuclear import factors by CBP/p300. Curr Biol 2000; 10: 467-470. (Pubitemid 30247335)
14. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25: 139-149. (Pubitemid 43077303)
15. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006; 26: 2782-2790.
16. Catania A, Iavarone C, Carlomagno SM, Chiariello M. Selective transcription and cellular proliferation induced by PDGF require histone deacetylase activity. Biochem Biophys Res Commun 2006; 343: 544-554.
17. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
18. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009; 114: 2926-2935.
19. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 2004; 279: 30358-30368. (Pubitemid 38937963)
20. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010; 285: 36129-36137.
21. Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999; 284: 479-482. (Pubitemid 29289619)
22. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005; 280: 11528-11534. (Pubitemid 40418464)
23. O'Shea JJ, Kanno Y, Chen X, Levy DE. Cell signaling. Stat acetylation-a key facet of cytokine signaling? Science 2005; 307: 217-218. (Pubitemid 40116227)
24. Kim DJ, Tremblay ML, Digiovanni J. Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 2010; 5: e10290.
25. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998; 78: 326-330. (Pubitemid 28445370)
26. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. (Pubitemid 29077388)
27. Lavelle D, Chen YH, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68: 170-178. (Pubitemid 32983205)
28. Ray S, Lee C, Hou T, Boldogh I, Brasier AR. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 2008; 36: 4510-4520.
29. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 2008; 47: 137-147. (Pubitemid 351231442)
30. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784-4795. (Pubitemid 47016131)
31. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417-428. (Pubitemid 29323855)
32. Li J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 2000; 19: 4342-4350. (Pubitemid 30623745)
33. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51. (Pubitemid 43054973)
34. McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004; 68: 1139-1144. (Pubitemid 39094279)
35. Schuringa JJ, Schepers H, Vellenga E, Kruijer W. Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 2001; 495: 71-76. (Pubitemid 32367976)
36. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell Jr JE. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci USA 1996; 93: 15092-15096. (Pubitemid 127606373)
37. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 2003; 111: 553-559. (Pubitemid 36228012)
38. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 2009; 23: 223-235.
39. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628-4635. (Pubitemid 44297814)
40. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5: 601-612.